Japan Approves SIGA Technologies Antiviral As First For Smallpox, Mpox
On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment TEPOXX (tecovirimat 200 mg capsules) for smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg.